Asset Details
Do you wish to reserve the book?
Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit
Do you wish to request the book?
Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit
2021
Overview
Proton pump inhibitors (PPIs), followed by histamine 2 receptor antagonists (H2RAs), are the most commonly used drugs to prevent gastrointestinal bleeding in critically ill patients through stress ulcer prophylaxis. The relative efficacy and drug-related adverse events of PPIs and H2RAs remain unclear. In this retrospective, observational, comparative cohort study, PPIs and H2RAs for stress ulcer prophylaxis in critically ill patients were compared using a common data model. After propensity matching, 935 patients from each treatment group (PPI or H2RA) were selected. The PPI group had a significantly higher 90-day mortality than the H2RA group (relative risk: 1.28;
P
= 0.01). However, no significant inter-group differences in the risk of clinically important gastrointestinal bleeding were observed. Moreover, there were no significant differences between the groups concerning the risk of pneumonia or
Clostridioides difficile
infection, which are known potential adverse events related to these drugs. Subgroup analysis of patients with high disease severity were consistent with those of the total propensity score-matched population. These findings do not support the current recommendations, which prefer PPIs for gastrointestinal bleeding prophylaxis in the intensive care unit.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Aged
/ Anti-Ulcer Agents - administration & dosage
/ Anti-Ulcer Agents - adverse effects
/ Anti-Ulcer Agents - therapeutic use
/ Bleeding
/ Clostridium Infections - epidemiology
/ Clostridium Infections - etiology
/ Female
/ Histamine Antagonists - administration & dosage
/ Histamine Antagonists - adverse effects
/ Histamine Antagonists - therapeutic use
/ Humanities and Social Sciences
/ Humans
/ Male
/ Patients
/ Peptic Ulcer Hemorrhage - drug therapy
/ Peptic Ulcer Hemorrhage - prevention & control
/ Proton Pump Inhibitors - administration & dosage
/ Proton Pump Inhibitors - adverse effects
/ Proton Pump Inhibitors - therapeutic use
/ Science
/ Ulcers
